Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A powerful cancer drug duo just cleared a major hurdle. Amgen's Imdelltra paired with AstraZeneca's Imfinzi significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial. The combo also boosted progression-free survival and response rates, with no new safety concerns flagged.
A late-stage clinical trial has shown that combining Amgen's targeted immunotherapy Imdelltra with AstraZeneca's cancer drug Imfinzi significantly improves overall survival in patients with extensive-stage small-cell lung cancer (ES-SCLC) — one of the most aggressive and difficult-to-treat cancers. The combination was tested as a maintenance therapy against Imfinzi alone in patients whose disease hadn't progressed after standard induction treatment.
Beyond overall survival, the drug duo also improved progression-free survival and response rates, with no new safety signals identified. Imdelltra is a bispecific antibody that bridges cancer cells and immune cells, enabling the body's immune system to attack tumors. Imfinzi, already approved for several cancers, works by blocking tumor mechanisms that help cancers evade the immune system.
Key Takeaways:
Why it matters: ES-SCLC has a notoriously poor prognosis and few effective maintenance options. This trial result could help establish a new standard of care, offering patients a meaningful survival benefit.
